NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
February 5, 2008 • Volume 5 / Number 3 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Combination Therapy for Invasive Bladder Cancer

Name of the Trial
Phase I/II Study of Paclitaxel and Radiotherapy with or without Trastuzumab (Herceptin) in Patients Who Have Undergone Prior Transurethral Bladder Resection for Muscle-Invasive Transitional Cell Carcinoma of the Bladder (RTOG-0524).  See the protocol summary at http://www.cancer.gov/clinicaltrials/RTOG-0524.

Dr. M. Dror Michaelson Principal Investigators
Drs. M. Dror Michaelson, Alan Pollack, and Douglas Dahl, Radiation Therapy Oncology Group

Why This Trial Is Important
Complete removal of the bladder, or cystectomy, is the most common treatment for bladder cancer that has invaded the organ’s muscle wall. However, to preserve the bladder and improve the quality of life for patients, doctors have developed a method for treating bladder cancer that uses a combination of chemotherapy and daily radiation therapy.

Previous clinical trials of this method have included only patients who were eligible for cystectomy, in the event that the bladder-preserving therapy failed. For patients who are not suitable for cystectomy, no standard treatment options currently exist.

In this trial, patients with invasive bladder cancer who are not suitable for cystectomy will be treated with the drug paclitaxel and daily radiation therapy. Also, patients whose tumors test positive for the protein HER2 will be treated with the monoclonal antibody trastuzumab (Herceptin).

Some studies have suggested that 40–80 percent of bladder cancer tumors produce increased amounts of HER2 and that patients with such tumors tend to fare poorly compared to patients whose tumors do not overexpress this protein. Trastuzumab binds to HER2 on the surface of tumor cells and initiates a cytotoxic process.

“Patients with muscle-invasive bladder cancer who are not suitable for surgery have few options for treatment,” said Dr. Michaelson. “With this trial we’re testing what we hope to be a fairly gentle means of treatment using combination therapy developed for bladder preservation.

“In addition to trying to establish a safe and well-tolerated regimen that can be tested in larger clinical trials, we hope to clarify the role of HER2 in bladder cancer and determine if trastuzumab can help improve outcomes for patients whose tumors overexpress that protein,” Dr. Michaelson added.

For More Information
See the list of entry criteria and trial contact information at http://cancer.gov/clinicaltrials/RTOG-0524 or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). The call is toll free and confidential.


An archive of "Featured Clinical Trial" columns is available at http://www.cancer.gov/clinicaltrials/ft-all-featured-trials.